Treatment of Pleural Mesothelioma: ASCO Guideline Update.

IF 42.1 1区医学 Q1 ONCOLOGY Journal of Clinical Oncology Pub Date : 2025-01-08 DOI:10.1200/JCO-24-02425

Hedy L Kindler, Nofisat Ismaila, Lyudmila Bazhenova, Quincy Chu, Jane E Churpek, Ibiayi Dagogo-Jack, Darren S Bryan, Michael W Drazer, Patrick Forde, Aliya N Husain, Jennifer L Sauter, Valerie Rusch, Penelope A Bradbury, B C John Cho, Marc de Perrot, Azam Ghafoor, David L Graham, Ola Khorshid, Alexandra Lebensohn, Julie White, Raffit Hassan

{"title":"Treatment of Pleural Mesothelioma: ASCO Guideline Update.","authors":"Hedy L Kindler, Nofisat Ismaila, Lyudmila Bazhenova, Quincy Chu, Jane E Churpek, Ibiayi Dagogo-Jack, Darren S Bryan, Michael W Drazer, Patrick Forde, Aliya N Husain, Jennifer L Sauter, Valerie Rusch, Penelope A Bradbury, B C John Cho, Marc de Perrot, Azam Ghafoor, David L Graham, Ola Khorshid, Alexandra Lebensohn, Julie White, Raffit Hassan","doi":"10.1200/JCO-24-02425","DOIUrl":null,"url":null,"abstract":"Purpose: To provide evidence-based recommendations to practicing physicians and others on the management of pleural mesothelioma (PM).Methods: ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pathology, cancer genetics, and advocacy experts to conduct an updated literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2016 through 2024. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.Results: The literature search identified 110 additional relevant studies to inform the evidence base for this guideline.Recommendations: Evidence-based recommendations were developed for surgical cytoreduction, immunotherapy, chemotherapy, pathology, and germline testing in patients with PM.Additional information is available at www.asco.org/thoracic-cancer-guidelines.","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2402425"},"PeriodicalIF":42.1000,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/JCO-24-02425","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To provide evidence-based recommendations to practicing physicians and others on the management of pleural mesothelioma (PM).

Methods: ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pathology, cancer genetics, and advocacy experts to conduct an updated literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2016 through 2024. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.

Results: The literature search identified 110 additional relevant studies to inform the evidence base for this guideline.

Recommendations: Evidence-based recommendations were developed for surgical cytoreduction, immunotherapy, chemotherapy, pathology, and germline testing in patients with PM.Additional information is available at www.asco.org/thoracic-cancer-guidelines.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

胸膜间皮瘤的治疗：ASCO指南更新。

目的：为执业医师和其他人员提供胸膜间皮瘤（PM）治疗的循证建议。方法：ASCO召集了一个由内科肿瘤学、胸外科、放射肿瘤学、病理学、癌症遗传学和倡导专家组成的专家小组，进行了最新的文献检索，包括2016年至2024年发表的系统综述、荟萃分析、随机对照试验、前瞻性和回顾性比较观察性研究。关注的结局包括生存、无病或无复发生存和生活质量。专家小组成员利用现有证据和非正式共识制定基于证据的指南建议。结果：文献检索确定了110项额外的相关研究，为本指南提供了证据基础。建议：针对PM患者的手术细胞减少、免疫治疗、化疗、病理和种系检测提出了基于证据的建议。更多信息请访问www.asco.org/thoracic-cancer-guidelines。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Clinical Oncology 医学-肿瘤学

CiteScore

41.20

自引率

2.20%

发文量

8215

审稿时长

2 months

期刊介绍： The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.